Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis

C Gidengil, MB Goetz, S Newberry, M Maglione, O Hall… - Vaccine, 2021 - Elsevier
Background Understanding the safety of vaccines is critical to inform decisions about
vaccination. Our objective was to conduct a systematic review of the safety of vaccines …

[HTML][HTML] Coping strategies for pertussis resurgence

X Nian, H Liu, M Cai, K Duan, X Yang - Vaccines, 2023 - mdpi.com
Pertussis (whooping cough) is a respiratory disease caused primarily by Bordetella
pertussis, a Gram-negative bacteria. Pertussis is a relatively contagious infectious disease in …

[HTML][HTML] Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization …

FP Havers - MMWR. Morbidity and mortality weekly report, 2020 - cdc.gov
Background Two Tdap vaccines are licensed for use in the United States. Boostrix
(GlaxoSmithKline) is approved for a single dose in persons aged≥ 10 years; Adacel (Sanofi …

[HTML][HTML] Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study

F Werner, N Zeschick, T Kühlein, P Steininger… - BMC medicine, 2023 - Springer
Background In the course of the SARS-CoV-2 pandemic, multiple vaccines were developed.
Little was known about reactogenicity and safety in comparison to established vaccines, eg …

[HTML][HTML] Improving vaccination rates in older adults and at-risk groups: focus on pertussis

JH Choi, J Correia de Sousa, M Fletcher… - Aging Clinical and …, 2022 - Springer
Despite the implementation of effective paediatric vaccination programmes, pertussis
remains a global health problem. Disease epidemiology has changed over time, shifting …

[HTML][HTML] Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular …

V Pool, A Tomovici, DR Johnson, DP Greenberg… - Vaccine, 2018 - Elsevier
Background In a prospective, randomized pivotal phase III clinical trial, the immunogenicity
and reactogenicity of a tetanus-diphtheria-acellular pertussis vaccine (Tdap) and a tetanus …

[HTML][HTML] Immunogenicity at delivery after Tdap vaccination in successive pregnancies

L De Weerdt, A Thiriard, E Leuridan… - Frontiers in …, 2024 - frontiersin.org
Background Tetanus, diphtheria, acellular pertussis (Tdap) vaccination is recommended to
be administered in every pregnancy. Although the safety of this strategy has been confirmed …

[HTML][HTML] Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria …

D Brandon, M Kimmel, SO Kuriyakose, L Kostanyan… - Vaccine, 2018 - Elsevier
Background Over the last decades, pertussis showed periodic increases in its incidence
among adults, despite being a vaccine-preventable disease. Methods This phase III …

Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States

FP Havers, BH Cho, JW Walker, S Hariri - Vaccine, 2020 - Elsevier
Abstract Background In the United States, persons≥ 11 years are recommended to receive
one dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) …

[HTML][HTML] Tetanus toxoid

T Rabadi, MF Brady - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Tetanus Toxoid - StatPearls - NCBI Bookshelf US flag An official website of the United
States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …